Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TTR | P02766 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL526119 | 0.97 | CA12 (0.52) | CA12CA7CA14SMN1; SMN2TSHR | |
| SCHEMBL27652381 | 0.89 | CA12 (0.46) | CA12CA7CA14SMN1; SMN2TSHR | |
| SCHEMBL26560789 | 0.77 | CA12 (0.50) | CA12CA7CA14SMN1; SMN2TSHR | |
| SCHEMBL108245 | 0.74 | CA12 (0.62) | CA12CA7CA14SMN1; SMN2TSHR | |
| SCHEMBL4442972 | 0.70 | CA12 (0.44) | CA12CA7CA14SMN1; SMN2TSHR | |
| SCHEMBL995945 | 0.69 | CA12 (0.62) | CA12CA7CA14SMN1; SMN2TSHR | |
| SCHEMBL19413262 | 0.67 | CA12 (0.52) | CA12CA7CA14SMN1; SMN2TSHR | |
| SCHEMBL19413263 | 0.67 | CA12 (0.52) | CA12CA7CA14SMN1; SMN2TSHR | |
| SCHEMBL4724826 | 0.67 | CA12 (1.00) | CA12CA7CA14SMN1; SMN2TSHR | |
| SCHEMBL19413304 | 0.67 | CA12 (0.52) | CA12CA7CA14SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180222892-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES, INC. | 2018-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222892-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, FADS2 | CA12 4719/4885CA7 4487/4885CA14 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.